Dogwood Therapeutics (DWTX) furnishes Q3 2025 results on 8-K

Dogwood Therapeutics (DWTX) furnished an update on its financial performance.

Rhea-AI Filing Summary

Dogwood Therapeutics (DWTX) furnished an update on its financial performance. On November 6, 2025, the company announced results for the third quarter ended September 30, 2025 via a press release attached as Exhibit 99.1. The information is expressly furnished, not filed under the Exchange Act, which means it is not subject to Section 18 liabilities and is not incorporated by reference into other filings.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did DWTX disclose in this 8-K?

The company furnished a press release announcing results for the quarter ended September 30, 2025.

Which exhibit contains Dogwood Therapeutics’ Q3 2025 results?

The results are in Exhibit 99.1 (press release dated November 6, 2025).

Is the information in the 8-K considered filed or furnished?

It is furnished, not filed, and therefore not subject to Section 18 liabilities or incorporated by reference.

What period do the disclosed results cover for DWTX (Nasdaq: DWTX)?

The disclosure pertains to the third quarter ended September 30, 2025.

Where can investors find the detailed financial results?

In the press release attached as Exhibit 99.1 to the 8-K.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/06/2025 - 09:15 AM EST Learn about SEC filing dates

0001818844false00018188442025-11-062025-11-06

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

​

FORM 8-K

​

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

​

Date of Report (Date of earliest event reported):  November 6, 2025

​

DOGWOOD THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in Charter)

​

​	​	​
Delaware	001-39811	85-4314201
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

​

​ ​	​
44 Milton Avenue Alpharetta, GA	30009
(Address of principal executive offices)	(Zip Code)

​

Registrant’s telephone number, including area code:  (866) 620-8655

​

(Former name or former address, if changed since last report): Not Applicable

​

Securities registered pursuant to Section 12(b) of the Act:

​

​	​	​
Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001	DWTX	Nasdaq Capital Market

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

​

​	​
☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
​	​
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
​	​
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
​	​
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company        ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.       ☐

​

​

​

​

Item 2.02 Results of Operations and Financial Condition.

On November 6, 2025, Dogwood Therapeutics, Inc. (the “Company”) issued a press release announcing the results of operations for the third quarter ended September 30, 2025. A copy of the press release is included as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference into this Item 2.02.

The information provided pursuant to this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Exchange Act.

​

Item 9.01 Financial Statements and Exhibits.

​

(d)Exhibits.

​

​	​	​
Exhibit Number		Description
99.1	​	Press Release of the Company, dated November 6, 2025 (furnished herewith).
104	​	Cover Page Interactive Data File (formatted in Inline XBRL)

​

​

​

2

SIGNATURES

​

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

​	​	​
	DOGWOOD THERAPEUTICS, INC.
	By:	/s/ Angela Walsh
	Name:	Angela Walsh
​	Title:	Chief Financial Officer, Corporate Secretary and Treasurer
November 6, 2025	​	​

​

​

​

​

​

​

​

3